Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Central Pharmaceuticals's FCF Margin % or its related term are showing as below:
DHA:CENTRALPHL'
s FCF Margin % Range Over the Past 10 Years
Min: -15.45 Med: -1.35 Max: 5.06
Current: 0.02
During the past 13 years, the highest FCF Margin % of Central Pharmaceuticals was 5.06%. The lowest was -15.45%. And the median was -1.35%.
DHA:CENTRALPHL's FCF Margin % is ranked worse than 57.63% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.57
vs DHA:CENTRALPHL: 0.02
Central Pharmaceuticals FCF Margin % Related Terms
Central Pharmaceuticals FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:CENTRALPHL vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Central Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Central Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Central Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Central Pharmaceuticals (DHA:CENTRALPHL) has a FCF Margin % of 0.07% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Central Pharmaceuticals and its competitors. According to the industry distribution chart, Central Pharmaceuticals ranks #555 out of 963 companies in the Drug Manufacturers industry, placing it in the top 57.6%.
Is Central Pharmaceuticals' FCF Margin % too high?
Central Pharmaceuticals' current FCF Margin % is 0.07%. The Drug Manufacturers industry median FCF Margin % is 2.57. Central Pharmaceuticals' value of 0.07% is 97.3% below this industry median. Based on the distribution chart, Central Pharmaceuticals ranks #555 out of 963 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Central Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Central Pharmaceuticals ranks #555 out of 963 companies for FCF Margin %. This places Central Pharmaceuticals in the lower half of its industry. The industry median FCF Margin % is 2.57. Central Pharmaceuticals' value of 0.07% is 97.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Central Pharmaceuticals's current FCF Margin % of 0.07% is 97.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Central Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Pharmaceuticals's current FCF Margin % is 0.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Fairly Valued. The stock's GF Value™ is BDT12.04, compared to a current price of BDT11.50 — trading 4.5% below its estimated fair value. The current FCF Margin % is 0.07% and 97.3% below the Drug Manufacturers industry median of 2.57. Central Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current FCF Margin % is 0.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?
Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT11.50 is trading 4.5% below its estimated GF Value™ of BDT12.04.
GuruFocus considers Central Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:CENTRALPHL:
FCF Margin %: 0.07%
GF Value™: BDT12.04 vs. price of BDT11.50 (4.5% below fair value)
Industry Position: 97.3% below the Drug Manufacturers median (#555 of 963)
No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
66GF Score
Get the complete analysis for DHA:CENTRALPHL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:CENTRALPHL has been successfully added to your 
